Stock Story -
Skincare company BeautyHealth (NASDAQ:SKIN) will be reporting results tomorrow afternoon. Here’s what you need to know.
BeautyHealth missed analysts’ revenue expectations by 8% last quarter, reporting revenues of $90.59 million, down 22.9% year on year. It was a disappointing quarter for the company, with revenue guidance for next quarter missing analysts’ expectations.
Is BeautyHealth a buy or sell going into earnings? Find out by reading the original article on StockStory, it’s free.
This quarter, analysts are expecting BeautyHealth’s revenue to decline 21.1% year on year to $76.82 million, a reversal from the 9.7% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.05 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BeautyHealth has missed Wall Street’s revenue estimates three times over the last two years.
Looking at BeautyHealth’s peers in the personal care segment, some have already reported their Q3 results, giving us a hint as to what we can expect. e.l.f. (NYSE:ELF) delivered year-on-year revenue growth of 39.7%, beating analysts’ expectations by 4%, and Herbalife (NYSE:HLF) reported a revenue decline of 3.2%, falling short of estimates by 1%. e.l.f. traded up 11.5% following the results while Herbalife was also up 10.2%.
Read the full analysis of e.l.f.’s and Herbalife’s results on StockStory.
Investors in the personal care segment have had steady hands going into earnings, with share prices flat over the last month. BeautyHealth is up 3.8% during the same time and is heading into earnings with an average analyst price target of $1.96 (compared to the current share price of $1.63).